Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.71 |
| ▸ | HRH2 | P25021 | 16/20 | 0.71 |
| ▸ | HRH1 | P35367 | 16/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491586 | 0.94 | HRH3 (0.68) | HRH3HRH2HRH1 | |
| SCHEMBL14150224 | 0.94 | HRH3 (0.68) | HRH3HRH2HRH1 | |
| SCHEMBL4494406 | 0.94 | HRH3 (0.68) | HRH3HRH2HRH1 | |
| SCHEMBL3828011 | 0.91 | HRH3 (0.71) | HRH3HRH2HRH1 | |
| SCHEMBL4684886 | 0.90 | HRH3 (0.66) | HRH3HRH2HRH1 | |
| Oxalic Acid SCHEMBL4495484 | 0.87 | HRH3 (0.61) | HRH3HRH2HRH1 | |
| Oxalic Acid SCHEMBL4500933 | 0.87 | HRH3 (0.65) | HRH3HRH2HRH1 | |
| SCHEMBL4622791 | 0.87 | HRH3 (0.59) | HRH3HRH2HRH1 | |
| SCHEMBL4622889 | 0.86 | HRH3 (0.65) | HRH3HRH2HRH1 | |
| SCHEMBL2051826 | 0.85 | HRH3 (0.58) | HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332910-B1 | New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-30 | — | — | EP | disclosed |
| US-8008337-B2 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-08-30 | — | — | US | disclosed |
| EP-2332910-A1 | New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-06-15 | — | — | EP | disclosed |
| US-20110136886-A1 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136886-A1 | Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them | HRH2, HRH4, HRH3 | HRH3 3/4885HRH2 1/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.